Llovet Bayer, Josep M
Life & Medical Sciences
Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS)
Phone 93-2279155
Email jmllovet@recerca.clinic.cat
Department Investigación traslacional en oncología hepática
Address Rosello 153
Keywords
Hepatocellular carcinoma
cholangiocarcinoma
signal transduction pathways
molecular targeted therapies
molecular classification
trial design
genomics
gene signatures
translational research
mTOR signaling
Wnt signaling
IGF signaling
miRNA
nanooncology
Short biography
Josep M Llovet, MD, PhD is ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the Univ.Barcelona. Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). He has published 359 manuscripts (scopus citations:112,377; h-index:134; IF:8,590). Top 1% most cited researcher globally by Clarivate Analytics (2014-23), and world most cited investigator in liver cancer. Major achievements: a) Defining molecular and immune classes of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), b) discovery of drivers as therapeutic targets in liver cancer, and c) Establishing standard therapies for HCC, such as sorafenib, regorafenib, ramucirumab and chemoembolization. He is Editor-in-Chief of J HEP Reports, Founder and President of ILCA (2006-13), delivered > 700 lectures, and PI of ~100 competitive grants [coordinator of 2 European FP7 & Horizon Europe grants and 2 NIH-RO1].